95 related articles for article (PubMed ID: 6292759)
1. [Evaluation of sulocton action in patients with atherosclerotic brain ischemia].
Karwowski B; Jura E; Krasicka J; Kruszewska J; Laskowska-Studniarska W; Szymchel J; Nielubowiczowa H
Neurol Neurochir Pol; 1982; 16(4):237-43. PubMed ID: 6292759
[TBL] [Abstract][Full Text] [Related]
2. [Hemorrheological survey in a group with arteriosclerotic vascular disease treated with suloctidil].
Caimi G; Catania A; Frazzetta F; Capobianco D; Francavilla G; Romano A; Sarno A
Ric Clin Lab; 1983; 13 Suppl 3():465-8. PubMed ID: 6324326
[TBL] [Abstract][Full Text] [Related]
3. [Suloctidil (sulocton) in the treatment of atherosclerotic neurasthenic syndromes].
Prusiński A; Kotwica S; Niewodniczy A; Split W
Wiad Lek; 1982 May; 35(3-4):201-5. PubMed ID: 6287740
[No Abstract] [Full Text] [Related]
4. [Clinical trial of suloctidil (sulocton) for the treatment of migraine (preliminary report)].
Prusiński A
Neurol Neurochir Pol; 1981; 15(3):309-11. PubMed ID: 6273762
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic use of a new vasoactive drug in cerebral vascular diseases in elderly patients].
Petronio G; Scali G; Casa B; Nonis E
Clin Ter; 1980 Aug; 94(4):427-44. PubMed ID: 6257445
[No Abstract] [Full Text] [Related]
6. [Further observations on the use of Suloctidil (Sulocton) in the treatment of migraine].
Prusiński A; Durko A; Głuszcz-Zielińska A; Szymańska R
Wiad Lek; 1984 Dec; 37(23):1857-9. PubMed ID: 6099634
[No Abstract] [Full Text] [Related]
7. [Chronic senile cerebrovascular insufficiency. Effects of suloctidil and pentoxifylline on erythrocyte deformability].
Pilla G; Ciaponi A; Migliavacca A; Bonora C
Ric Clin Lab; 1983; 13 Suppl 3():459-64. PubMed ID: 6324325
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patients.
Roncucci R; De Hertogh R; Dormandy JA; Doumont J; Gurewich V; Lambelin G; Lansen J; Rottiers R; Souridis E; Van Stalle F; Versee L
Arzneimittelforschung; 1979; 29(4):682-4. PubMed ID: 582768
[TBL] [Abstract][Full Text] [Related]
9. [Role of the blood platelets in the atherosclerotic process and clinical use of a new drug, Suloctidil, with anti-aggregating activity].
Armani U; Piana A
Arch Maragliano Patol Clin; 1979; 35(2):57-62. PubMed ID: 233645
[No Abstract] [Full Text] [Related]
10. Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.).
Moriau M; Col-De Beys C; Pardonge E; Ferrant A
Thromb Haemost; 1982 Feb; 47(1):27-31. PubMed ID: 6280332
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic-pharmacological effect on cerebral circulation evaluated by means of computerized CW Doppler signal spectrum analysis--first experiments on the action of Suloctidil.
De Fabritiis A; Guastarobba A; Scondotto G; Borgatti E
Monogr Neural Sci; 1984; 11():243-50. PubMed ID: 6330541
[No Abstract] [Full Text] [Related]
12. Double-blind trial of suloctidil versus placebo in moderate to severe mental deterioration.
Baro F; Malfroid M; Waegemans T; Cox JP
Pharmatherapeutica; 1985; 4(6):399-404. PubMed ID: 3001778
[TBL] [Abstract][Full Text] [Related]
13. Suloctidil: long-term trial in the aged. Study of microcirculation, viscosity, red cell deformability, fibrinolysis and lipid fractions.
Merchan R; Zurita IE; Martinez JF
Arzneimittelforschung; 1985; 35(5):855-7. PubMed ID: 2992530
[TBL] [Abstract][Full Text] [Related]
14. [Use of sermion in cerebral atherosclerosis patients with a history of ischemic stroke].
Tsimenko OA; Sosnov IuD; Kharchenko AP; Gaĭduk IuS
Vrach Delo; 1988 Jul; (7):24-7. PubMed ID: 3188456
[No Abstract] [Full Text] [Related]
15. [Medium term treatment with suloctidil in obliterating arteriopathies of the lower limbs. Personal experience].
Marongiu G; Dettori G; Gadeddu A; Noya G; Angius P; Biglioli P
Minerva Cardioangiol; 1983; 31(7-8):407-10. PubMed ID: 6316206
[No Abstract] [Full Text] [Related]
16. [Suloctidil in the treatment of focal cerebral ischemia].
Bartko D; Zúzi M; Brezná M; Trávniková M; Porubec V
Cesk Neurol Neurochir; 1984 Mar; 47(2):103-8. PubMed ID: 6323038
[No Abstract] [Full Text] [Related]
17. [Effects of suloctidil therapy on platelet function in patients with on obliterating arteriopathy of the lower limbs].
Davì G; Pinto A; Novo S; Avellone G; Galati D; Mazzola A
Clin Ter; 1982 Oct; 103(2):131-7. PubMed ID: 6295693
[No Abstract] [Full Text] [Related]
18. Suloctidil therapy in migraine: an open pilot study.
Prusiński A; Durko A; Głuszcz-Zielińska A; Szymańska R
Curr Med Res Opin; 1983; 8(9):631-3. PubMed ID: 6321107
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacotherapy of endothelial dysfunction in patients with atherosclerotic brain ischemia].
Fedin AI; Starykh EP; Parfenov AS; Mironova OP; Abdrakhmanova EK; Starykh EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10):45-8. PubMed ID: 24300805
[TBL] [Abstract][Full Text] [Related]
20. [Protective effect of suloctidil against cerebral hypoxia (author's transl)].
Hori N; Nishi H; Katsuda N
Nihon Yakurigaku Zasshi; 1980 Oct; 76(7):655-65. PubMed ID: 6260603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
